This might include looking at headcount, training, and facility
needs that will have to be in place to support GLP in the laboratory.
Novo Nordisk decided to test the drug based on studies looking at electronic health records that found people taking semaglutide for diabetes and other indications had a lower chance
of developing Alzheimer’s. Higher doses of semaglutide,
such as those in Wegovy, are associated with a greater likelihood of
fatigue compared to lower doses like Ozempic. Fatigue isn’t an officially listed side effect of GLP-1 medications, but many people experience fatigue, especially
during the first few weeks of treatment or when starting
higher doses. It’s important to consult a healthcare provider to determine the appropriate semaglutide dose and to gradually adjust the dose to
help minimize side effects like fatigue. GLP-1 medicines
help the pancreas make insulin after you eat-if those insulin-making cells are
still working. Emerging studies are exploring whether GLP-1s could also help slow the
progression of kidney disease, though current findings are still preliminary.
In people without diabetes, other hormones-including GLP-1, glucagon and amylin-also help with appetite,
digestion and sugar balance. GLP-1 medications mimic natural hormones that help regulate appetite, insulin production,
and blood sugar levels, making them effective for managing type 2 diabetes and supporting weight loss.
https://docs.brdocsdigitais.com/index.php/Who_Is_GLP-1%3F